The cost of treating diabetes and its complications adds up to $116 billion, with roughly one-third spent on diabetic foot ulcers, according to a 2007 study. A Canadian medical device company has developed a pressure-sensitive wireless alert system aimed at diabetics who fit into a high-risk group for developing these foot ulcers, which can lead to amputation.
The goal of Orpyx Medical Technologies‘ Surrosense RX device is to alert patients to an impending foot ulcer so they can seek medical attention before it develops on the skin’s surface. It is also interested in finding a U.S mobile health partner with experience with apps and interoperability.
The patients that fit into this group are those diagnosed with type 1 or type 2 diabetes and peripheral neuropathy. People with this condition have little or no sensitivity in the vulnerable area because of the condition, increasing the likelihood of a recurrence. “Typically they have had an ulceration heal and are very motivated to prevent a second outbreak,” said Amanda Hehr, the vice president of marketing for Calgary-based Orpyx.
Another product being developed by the company also ties in with foot ulcers. The SurroGait RX device sends a light vibration to the back when the person is nearing a danger zone for developing an ulcer on their foot. It’s also designed to improve gait and balance for people with peripheral neuropathy. Over time, the device is intended to educate users to feel the sensation they would normally feel on their feet on their backs. It is intended to reduce the risk of falls because of the lack of sensation by the feet.
Hehr spoke with MedCity News about the device and strategic partnerships it’s interested in forging with U.S. companies.
Reserve your seat now for MedCity CONVERGE, to be held July 9-10 in Philadelphia. Discover strategies, solutions and startups in healthcare innovation. Be a part of this gathering where the entire healthcare ecosystem converges.